Effects of the dystrophin hydrophobic regions in the pathogenesis of Duchenne muscular dystrophy 
A three-dimensional reconstruction verification

doi:10.3969/j.issn.2095-4344.2013.50.014

Abstract

Abstract:

BACKGROUND: Duchenne muscular dystrophy is recognized as a fatal X-linked recessive inheritance. It is caused by the dystrophin gene mutation, resulting in the deficiency of dystrophin and consequent degeneration and necrosis of muscle fibers gradually. Becker muscular dystrophy is also caused by the mutation of the same gene, but presented with less severe clinical symptoms compared with Duchenne muscular dystrophy. Frameshift mutation destroys the reading frames, and thus the translation cannot proceed smoothly to transcript functional proteins. In-frame mutation cannot destroy the reading frames and hence the translation can proceed smoothly. But in-frame mutation involves the whole hydrophobic regions. The three-dimensional structure of these regions and their functionality are not interpreted clearly. The effects of these regions on disease development need to be clarified in detail from the point of structure and function.
OBJECTIVE: By analyzing Kate and Dolittle scale mean hydrophobicity profile, to investigate the dystrophin hydrophobic regions using Swiss-model so as to provide the supplement explanation on the reading frame rule.
METHODS: Form 2002 to 2013, 1 038 cases diagnosed as Duchenne muscular dystrophy or Becker muscular dystrophy were collected in the First Hospital of Sun Yat-sen University in China and Leiden DMD information database was searched with deletion of codon mutation information available. The correlation between clinical types and genotypes was analyzed upon resources collected above. The mean hydrophobicity profile of dystrophin was analyzed by Bioedit as well as the reconstruction of hydrophobic domains using Swiss-model. Thus, the important functional domain of dystrophin was confirmed by analysis and the correlation between clinical types and genotypes.
RESULTS AND CONCLUSION: Four hydrophobic regions were confirmed: Calponin homology domain CH2 on actin-binding domain, repeat 16 domain, Hinge Ⅲ domain and EF Hand domain. Duchenne muscular dystrophy was developed as a result of the destruction of the 1st, 2nd and 4th hydrophobic regions which were the conjunction of dystrophin and associated protein in dystrophin-glycoprotein complex. When the 3rd hydrophobic was deleted, the repeat domain located on central rob domain remained its continuity so that the clinical symptoms were less severe. These findings indicate that the dystrophin hydrophobic regions act as an important role on the pathogenesis of Duchenne muscular dystrophy.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: muscular dystrophy, Duchenne, hydrophobic and hydrophilic interactions, protein structure, tertiary, protein conformation

CLC Number:

R318

Liang Ying-yin, Cao Ji-qing, Yang Juan, Zhang Cheng. Effects of the dystrophin hydrophobic regions in the pathogenesis of Duchenne muscular dystrophy
A three-dimensional reconstruction verification[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.50.014.

Figures/Tables 4

References

[1] Pane M, Lombardo ME, Alfieri P, et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J Pediatr. 2012;161(4):705-709.e1.

[2] Magri F, Govoni A, D'Angelo MG, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258(9): 1610-1623.

[3] Escolar DM, Zimmerman A, Bertorini T, et al. Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial. Neurology. 2012;78(12):904-913.

[4] López-Hernández LB, van Heusden D, Soriano-Ursúa MA, et al. Genotype-phenotype discordance in a Duchenne muscular dystrophy patient due to a novel mutation: insights into the shock absorber function of dystrophin. Rev Neurol. 2011;52(12):720-724.

[5] Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond). 2011;1(9): 1217-1235.

[6] Scully MA, Cwik VA, Marshall BC, et al. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology. 2013;80(6):583-589.

[7] Soltanzadeh P, Friez MJ, Dunn D, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord. 2010;20(8):499-504.

[8] Basumatary LJ, Das M, Goswami M, et al. Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India. J Neurosci Rural Pract. 2013; 4(2):227-229.

[9] Moore CJ, Winder SJ. The inside and out of dystroglycan post-translational modification. Neuromuscul Disord. 2012; 22(11):959-965.

[10] Janke A, Upadhaya R, Snow WM, et al. A new look at cytoskeletal NOS-1 and β-dystroglycan changes in developing muscle and brain in control and mdx dystrophic mice. Dev Dyn. 2013. in press.

[11] Kalman L, Leonard J, Gerry N, et al. Quality assurance for Duchenne and Becker muscular dystrophy genetic testing: development of a genomic DNA reference material panel. J Mol Diagn. 2011;13(2):167-174.

[12] Rani AQ, Sasongko TH, Sulong S, et al. Mutation spectrum of dystrophin gene in malaysian patients with Duchenne/Becker muscular dystrophy. J Neurogenet. 2013;27(1-2):11-15.

[13] Lee BL, Nam SH, Lee JH, et al. Genetic analysis of dystrophin gene for affected male and female carriers with Duchenne/Becker muscular dystrophy in Korea. J Korean Med Sci. 2012;27(3):274-280.

[14] de Brouwer AP, Nabuurs SB, Verhaart IE, et al. A 3-base pair deletion, c.9711_9713del, in DMD results in intellectual disability without muscular dystrophy. Eur J Hum Genet. 2013. in press.

[15] Kesari A, Pirra LN, Bremadesam L, et al. Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat. 2008;29(5):728-737.

[16] Zhang D, Cui S, Guo H, et al. Genomic structure, characterization and expression analysis of a manganese superoxide dismutase from pearl oyster Pinctada fucata. Dev Comp Immunol. 2013;41(4):484-490.

[17] Yang J, Li SY, Li YQ, et al. MLPA-based genotype-phenotype analysis in 1053 Chinese patients with DMD/BMD. BMC Med Genet. 2013;14:29.

[18] Tuffery-Giraud S, Béroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009;30(6): 934-945.

[19] Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157(1): 105-132.

[20] Ghose S, Tao Y, Conley L, et al. Purification of monoclonal antibodies by hydrophobic interaction chromatography under no-salt conditions. MAbs. 2013;5(5):795-800.

[21] Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat. 2005;26(2):63-68.

[22] Fokkema IF, Taschner PE, Schaafsma GC, et al. LOVD v.2.0: the next generation in gene variant databases. Hum Mutat. 2011;32(5):557-563.

[23] Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol. 1993;240(2):98-104.

[24] Norwood FL, Sutherland-Smith AJ, Keep NH, et al. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure. 2000; 8(5):481-491.

[25] Zhang C, Cai JH, Liu ZL, et al. The relationship between dystrophin hydrophobic structure and DMD/BMD. Zhongshan Yike Daxue Xuebao. 1993;14(2):160.

[26] Kiefer F, Arnold K, Künzli M, et al. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009;37(Database issue):D387-392.

[27] Goodsell DS. Representing structural information with RasMol. Curr Protoc Bioinformatics. 2005;Chapter 5:Unit 5.4.

[28] Kretsinger RH, Nockolds CE. Carp muscle calcium-binding protein. II. Structure determination and general description. J Biol Chem. 1973;248(9):3313-3326.

[29] Heidarsson PO, Otazo MR, Bellucci L, et al. Single-Molecule Folding Mechanism of an EF-Hand Neuronal Calcium Sensor. Structure. 2013;21(10):1812-1821.

[30] Bork P, Sudol M. The WW domain: a signalling site in dystrophin? Trends Biochem Sci. 1994;19(12):531-533.

[31] Hiraki T, Abe F. Overexpression of Sna3 stabilizes tryptophan permease Tat2, potentially competing for the WW domain of Rsp5 ubiquitin ligase with its binding protein Bul1. FEBS Lett. 2010;584(1):55-60.

[32] Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 1988;53(2):219-228.

[33] Gumerson JD, Michele DE. The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol. 2011;2011:210797.

[34] Mondal J, Morrone JA, Berne BJ. How hydrophobic drying forces impact the kinetics of molecular recognition. Proc Natl Acad Sci U S A. 2013;110(33):13277-13282.

[35] Norwood FL, Sutherland-Smith AJ, Keep NH, et al. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure. 2000; 8(5): 481-491.

[36] Singh SM, Mallela KM. The N-terminal actin-binding tandem calponin-homology (CH) domain of dystrophin is in a closed conformation in solution and when bound to F-actin. Biophys J. 2012;103(9):1970-1978.

[37] Legrand B, Giudice E, Nicolas A, et al. Computational study of the human dystrophin repeats: interaction properties and molecular dynamics. PLoS One. 2011;6(8):e23819.

[38] Acsadi G, Moore SA, Chéron A, et al. Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild Becker muscular dystrophy. J Biol Chem. 2012;287(22):18153-18162.

[39] Mirza A, Menhart N. Stability of dystrophin STR fragments in relation to junction helicity. Biochim Biophys Acta. 2008; 1784(9):1301-1309.

[40] Lai Y, Zhao J, Yue Y, et al. α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci U S A. 2013;110(2):525-530.

[41] Harper SQ. Molecular dissection of dystrophin identifies the docking site for nNOS. Proc Natl Acad Sci U S A. 2013; 110(2):387-388.

[42] Cazzella V, Martone J, Pinnarò C, et al. Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther. 2012;20(11):2134-2142.

[43] Sahni N, Mangat K, Le Rumeur E, et al. Exon edited dystrophin rods in the hinge 3 region. Biochim Biophys Acta. 2012;1824(10):1080-1089.

[44] Banks GB, Judge LM, Allen JM, et al. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 2010;6(5):e1000958.

[45] Carsana A, Frisso G, Tremolaterra MR, et al. Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. Ann Hum Genet. 2005;69(Pt 3):253-259.

[46] Nicholson LV, Johnson MA, Bushby KM, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. J Med Genet. 1993;30(9):737-744.

[47] Stahelin RV. Lipid binding domains: more than simple lipid effectors. J Lipid Res. 2009;50 Suppl:S299-304.

[48] Aoki Y, Nakamura A, Yokota T, et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther. 2010;18(11):1995-2005.

[49] Chung W, Campanelli JT. WW and EF hand domains of dystrophin-family proteins mediate dystroglycan binding. Mol Cell Biol Res Commun. 1999;2(3):162-171.

[50] Hnia K, Zouiten D, Cantel S, et al. ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. Biochem J. 2007;401(3):667-677.

[51] Huang X, Poy F, Zhang R, et al. Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat Struct Biol. 2000;7(8):634-638.

[52] Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta. 2013. in press.

[53] Cirak S, Feng L, Anthony K, et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther. 2012;20(2):462-467.

[54] R Mendell J, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013. in press.